Michael Breckwoldt

Dr. Michael Breckwoldt

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Nature
Verified
Journal Article
Open access
PDF file
MPMichael Platten
Michael Platten
LBLukas Bunse
Lukas Bunse
AWAntje Wick
Antje Wick
TBTheresa Bunse
Theresa Bunse
LCLucian Le Cornet
Lucian Le Cornet
WWWolfgang Wick
Wolfgang Wick
Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma1–3. The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocompatibility complex (MHC) class II4,5. An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against IDH1(R132H)+ tumours in syngeneic MHC-humanized mice4,6–8. Here we describe a multicentre, single-arm, open-label, first-in-humans phase I trial that we carried out in 33 patients with newly diagnosed World Health Organization grade 3 and 4 IDH1(R132H)+ astrocytomas (Neurooncology Working Group of the German Cancer Society trial 16 (NOA16), ClinicalTrials.gov identifier NCT02454634). The trial met its primary safety endpoint, with vaccine-related adverse events restricted to grade 1. Vaccine-induced immune responses were observed in 93.3% of patients across multiple MHC alleles. Three-year progression-free and death-free rates were 0.63 and 0.84, respectively. Patients with immune responses showed a two-year progression-free rate of 0.82. Two patients without an immune response showed tumour progression within two years of first diagnosis. A mutation-specificity score that incorporates the duration and level of vaccine-induced IDH1(R132H)-specific T cell responses was associated with intratumoral presentation of the IDH1(R132H) neoantigen in pre-treatment tumour tissue. There was a high frequency of pseudoprogression, which indicates intratumoral inflammatory reactions. Pseudoprogression was associated with increased vaccine-induced peripheral T cell responses. Combined single-cell RNA and T cell receptor sequencing showed that tumour-infiltrating CD40LG+ and CXCL13+ T helper cell clusters in a patient with pseudoprogression were dominated by a single IDH1(R132H)-reactive T cell receptor.

14 December 2022 in Nature
Verified
Journal Article
Closed access
PDF file
DHDavid Hausmann
David Hausmann
DHDirk C. Hoffmann
Dirk C. Hoffmann
VVVarun Venkataramani
Varun Venkataramani
EJErik Jung
Erik Jung
SHSandra Horschitz
Sandra Horschitz
FWFrank Winkler
Frank Winkler

18 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KAKatrin Aslan
Katrin Aslan
VTVerena Turco
Verena Turco
JBJens Blobner
Jens Blobner
JSJana K. Sonner
Jana K. Sonner
ALAnna Rita Liuzzi
Anna Rita Liuzzi
MPMichael Platten
Michael Platten
Intrinsic malignant brain tumors, such as glioblastomas are frequently resistant to immune checkpoint blockade (ICB) with few hypermutated glioblastomas showing response. Modeling patient-individual resistance is challenging due to the lack of predictive biomarkers and limited accessibility of tissue for serial biopsies. Here, we investigate resistance mechanisms to anti-PD-1 and anti-CTLA-4 therapy in syngeneic hypermutated experimental gliomas and show a clear dichotomy and acquired immune heterogeneity in ICB-responder and non-responder tumors. We made use of this dichotomy to establish a radiomic signature predicting tumor regression after pseudoprogression induced by ICB therapy based on serial magnetic resonance imaging. We provide evidence that macrophage-driven ICB resistance is established by CD4 T cell suppression and Treg expansion in the tumor microenvironment via the PD-L1/PD-1/CD80 axis. These findings uncover an unexpected heterogeneity of response to ICB in strictly syngeneic tumors and provide a rationale for targeting PD-L1-expressing tumor-associated macrophages to overcome resistance to ICB.

21 September 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NGNiklas Grassl
Niklas Grassl
IPIsabel Poschke
Isabel Poschke
KLKatharina Lindner
Katharina Lindner
LBLukas Bunse
Lukas Bunse
IMIris Mildenberger
Iris Mildenberger
KSKatharina Sahm
Katharina Sahm
Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide vaccine (H3K27M-vac) induces mutation-specific immune responses that control H3K27M+ tumors in major histocompatibility complex-humanized mice. Here we describe a first-in-human treatment with H3K27M-vac of eight adult patients with progressive H3K27M+ diffuse midline glioma on a compassionate use basis. Five patients received H3K27M-vac combined with anti-PD-1 treatment based on physician’s discretion. Repeat vaccinations with H3K27M-vac were safe and induced CD4+ T cell-dominated, mutation-specific immune responses in five of eight patients across multiple human leukocyte antigen types. Median progression-free survival after vaccination was 6.2 months and median overall survival was 12.8 months. One patient with a strong mutation-specific T cell response after H3K27M-vac showed pseudoprogression followed by sustained complete remission for >31 months. Our data demonstrate safety and immunogenicity of H3K27M-vac in patients with progressive H3K27M+ diffuse midline glioma.

31 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KKKlara Kirschbaum
Klara Kirschbaum
JSJana K. Sonner
Jana K. Sonner
MZMatthias W. Zeller
Matthias W. Zeller
KDKatrin Deumelandt
Katrin Deumelandt
JBJulia Bode
Julia Bode
Michael BreckwoldtMichael Breckwoldt
Michael Breckwoldt
Innate immune cells play a key role in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Current clinical imaging is restricted to visualizing secondary effects of inflammation, such as gliosis and blood–brain barrier disruption. Advanced molecular imaging, such as iron oxide nanoparticle imaging, can allow direct imaging of cellular and molecular activity, but the exact cell types that phagocytose nanoparticles in vivo and how phagocytic activity relates to disease severity is not well understood. In this study we used MRI to map inflammatory infiltrates using high-field MRI and fluorescently labeled cross-linked iron oxide nanoparticles for cell tracking. We confirmed nanoparticle uptake and MR detectability ex vivo. Using in vivo MRI, we identified extensive nanoparticle signal in the cerebellar white matter and circumscribed cortical gray matter lesions that developed during the disease course (4.6-fold increase of nanoparticle accumulation in EAE compared with healthy controls, P < 0.001). Nanoparticles showed good cellular specificity for innate immune cells in vivo, labeling activated microglia, infiltrating macrophages, and neutrophils, whereas there was only sparse uptake by adaptive immune cells. Importantly, nanoparticle signal correlated better with clinical disease than conventional gadolinium (Gd) imaging (r, 0.83 for nanoparticles vs. 0.71 for Gd-imaging, P < 0.001). We validated our approach using the Food and Drug Administration-approved iron oxide nanoparticle ferumoxytol. Our results show that noninvasive molecular imaging of innate immune responses can serve as an imaging biomarker of disease activity in autoimmune-mediated neuroinflammation with potential clinical applications in a wide range of inflammatory diseases. Significance Multiple sclerosis is a devastating neurological condition that can affect the entire central nervous system. Innate immune cells mediate the underlying tissue damage, but visualizing these cellular culprits is currently not possible. Diagnosis and treatment monitoring are performed by MRI, but so far imaging markers are unspecific and based on secondary parameters (edema/gliosis; blood–brain barrier disruption). We used a nanoparticle-based approach to image brain-resident and infiltrating innate immune cells in inflammatory lesions. Nanoparticle uptake is specific for innate immune cells and correlates with clinical severity. Thus, targeting innate immunity by molecular imaging may serve as a direct marker of disease activity with the potential of clinical translation to a wide variety of inflammatory conditions for improved diagnosis and treatment monitoring.

11 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
VTVerena Turco
Verena Turco
KPKira Pfleiderer
Kira Pfleiderer
JHJessica Hunger
Jessica Hunger
NHNatalie K. Horvat
Natalie K. Horvat
KKKianush Karimian-Jazi
Kianush Karimian-Jazi
MPMichael Platten
Michael Platten
Glioblastoma, the most common and aggressive primary brain tumor type, is considered an immunologically “cold” tumor with sparse infiltration by adaptive immune cells. Immunosuppressive tumor-associated myeloid cells are drivers of tumor progression. Therefore, targeting and reprogramming intratumoral myeloid cells is an appealing therapeutic strategy. Here, we investigate a β-cyclodextrin nanoparticle (CDNP) formulation encapsulating the Toll-like receptor 7 and 8 (TLR7/8) agonist R848 (CDNP-R848) to reprogram myeloid cells in the glioma microenvironment. We show that intravenous monotherapy with CDNP-R848 induces regression of established syngeneic experimental glioma, resulting in increased survival rates compared with unloaded CDNP controls. Mechanistically, CDNP-R848 treatment reshapes the immunosuppressive tumor microenvironment and orchestrates tumor clearing by pro-inflammatory tumor-associated myeloid cells, independently of T cells and NK cells. Using serial magnetic resonance imaging, we identify a radiomic signature in response to CDNP-R848 treatment and ultrasmall superparamagnetic iron oxide (USPIO) imaging reveals that immunosuppressive macrophage recruitment is reduced by CDNP-R848. In conclusion, CDNP-R848 induces tumor regression in experimental glioma by targeting blood-borne macrophages without requiring adaptive immunity.